Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't know how accurate ihubs trades page is but if the buys are correct, we are looking at some possible new players in the game. Just hoping they are in it for the long haul...
1.9m buys vs 900k sells.
We could use some players committed to the cause. :)
Go PMCB - Long and Strong
A wise friend once told me that everything is a process. The fact that we are having more days of good volume tells me that the process of word of mouth may be working. Certainly word of mouth is the most powerful form of advertising and it may just be that we are attracting more believers.
I certainly hope this is the reason we are seeing a rise in volume. With all we have going on and the associated costs, the more support and stability for the stock the better to get this to market and patients.
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, stated, “Given all of the developments that have occurred since our last update, we believe it is an appropriate time to update our shareholders on developments and to highlight and briefly summarize what is in store for PharmaCyte Biotech in the coming days. Before doing so, however, we would like to address two issues that reportedly are of significant concern to a number of our shareholders. The first has to do with whether a reverse stock split is imminent. The second is whether we have access to capital to move forward with our clinical trials. PharmaCyte Biotech has no current plans to effectuate a reverse stock split. In addition, our cash position remains strong and our ability to raise capital continues to be very favorable.”
“As to the update, we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future. Our priority is and always has been to maximize shareholder value, and we are working diligently to reach that objective,” added Mr. Waggoner.
Progress in the Cancer Program
PharmaCyte Biotech’s treatment (Cell-in-a-Box(R) plus low-doses of ifosfamide) for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in late December of 2014.
On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box(R) plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S. is the third quarter of 2015.
Preparations for the Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer are ongoing. Major documents, including the Investigators Brochure and a clinical protocol (a recipe for conducting the clinical trial) are in preparation, with the assistance of Clinical Network Services (CNS) – one of Australia’s leading Clinical Research Organizations. The target date for the initiation of the Phase 2b clinical trial in Australia is the third quarter of 2015.
We initially reported that we expected to begin our Phase 2b clinical trial in the first quarter of 2015; however, we are awaiting the Good Manufacturing Practices (GMP) regulatory approval process that our partner, Austrianova, is currently involved with in order to get the GMP-compliant facility at the Thai Science Park in Bangkok, Thailand, approved to produce Cell-in-a-Box(R) capsules for human clinical trials. Austrianova believes the process will now be completed in the third quarter of 2015.
Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box(R) technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers – such as brain and pancreatic cancer.
Progress in the Diabetes Program
Studies are in progress at the University of Veterinary Medicine, Vienna (UVM) to determine if Melligen (human, non-pancreatic, insulin-producing) cells are tumorigenic and to establish parameters by which these cells (human, non-pancreatic, insulin-producing) can produce and store insulin in response to glucose levels in their surroundings. The coordinator for these studies is Dr. Constantine Konstantoulas of UVM.
An exclusive license to use the Melligen cells developed by Prof. Ann Simpson of the University of Technology Sydney (UTS) in Australia has been obtained from UTS by PharmaCyte Biotech from UTS.
Dr. Eva-Maria Brandtner has been appointed Director of the Diabetes Research Program. Dr. Brandtner, presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria, was responsible for studies with the Melligen cells during her previous tenure with our partner, Austrianova, at its Chief Scientist.
Developments at the Corporate Level
The Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to emphasize that it has fully transitioned from a nutraceutical company to a purely biotechnology company.
Changes have been and are being made at the Board of Directors level, with additional member candidates to the Board in their final interview process; these new members will be widely experienced in the life sciences.
Waggoner concluded, “We are pleased to offer this update to our shareholders. We trust that they will agree that significant progress is being made on all fronts.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
That's right Pete and Bill.
:)
Nice volume today - 2.9M. 100 day, 2.2M - 22 day 1.7 M.
"Down days on low volume is of no concern
Down days on heavy volume is of great concern (very bearish sign)
Up days on low volume is of no concern
Up days on heavy volume is of great concern (very bullish sign)"
Bill
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111955947
Maybe not very bullish today but a good sign, imo.
Very well said Bio...
:)
Pete, you are very fortunate to be in a position to support PMCB as you do. Thanks...
Yes and they may be in the office sometime next week according to this email to mddoctor.
Either way, I am more concerned about what is happening in Scottsdale and Vienna.
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
Ghost office...yesterday I dropped an email to PMCB inquiring about PMCB HQRS being abandoned that's what a share holder ,who lives near by ,told us here.Well I got a quick statement: Dear Mr. Escobar,
Thanks for your inquiry. I can assure you that our office in Silver Spring, Maryland is not a "ghost office." However, most of us have been travelling since the middle of November of last year. Those travels have included trips to Thailand, Singapore, Sweden and throughout the United States. It has not been cost effective or an efficient use of our time to be in our office in Silver Spring.
Dr. Crabtree and I will be in New York and Boston next week. Thereafter, we are headed to our office in Silver Spring.
We appreciate you support of PharmaCyte Biotech......by the way was signed by KW......go PMCB!!!!!!!
mddoctor
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111651280
You are very welcome. Good to see you are still long and strong... :)
jz, here are the most recent notes from the EMA session.
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/03/WC500184524.pdf
From the research gate article, you can see that Dr Lohr was involved in the first preclinical study back in 1998 and wrote the following articles... Dr Lohr is the chair of our SAB...
https://www.researchgate.net/profile/Brian_Salmons/publication/236621026_GeneTher5_1070/links/004635186ada157d66000000.pdf
https://www.researchgate.net/profile/Brian_Salmons/publication/226494940_Cell_therapy_using_microencapsulated_293_cells_transfected_with_a_gene_construct_expressing_CYP2B1_an_ifosfamide_converting_enzyme_instilled_intra-arterially_in_patients_with_advanced-stage_pancreatic_carcinoma_a_phase_III_study/links/0c96051bc4242158d9000000.pdf
That is exactly what I was thinking and you said it so well... :)
Bavarian Nordic sponsored the Phase I/II trials in the late 90s. I have provided some great historical reading material to help you enjoy your weekend...
http://eunikfinance.blogspot.com/2014/03/nvlx-nuvilex-appoints-ceo-and-president.html
http://www.sentinext.com/index.php?option=com_content&view=article&id=28&Itemid=39
https://www.researchgate.net/profile/Brian_Salmons/publication/43129475_Therapeutic_application_of_cell_microencapsulation_in_cancer/links/00b4951e77ed34979b000000.pdf
http://www.medunigraz.at/partneringday/pdf_2006/L12_Austrianova_Murr.pdf
http://sgaustria.com/wp-content/uploads/2010/11/GMP-Production-of-an-encapsulated-cell-therapy-product.pdf
Very low volume today. Yesterday we more than doubled the 100 day average and today less than half of the 100 day average has been in play.
Well said Bill...
Thanks again...
Bill, this is data from the Phase I/II with Austrianova.
Cell in a Box(R) technology has already been proven. Austrianova went bankrupt before they could complete Phase 3. I believe Dr Von Hoff read these old reports and as a result, he decided to test the technology for "quality of life" treatments for malignant ascites and the associated pain.
I also believe our reports that the current studies with TD 2 are going well. With Dr Von Hoff's record, I also believe, if Cell in a Box(R) continues to be proven effective, we will have whatever funding is needed to get this to patients.
The data is available for everyone to see. The potential is undeniable. And Dr Von Hoff is a man on a mission. He did come to us...
http://160.153.35.100/pancreatic-cancer/
http://www.mdpi.com/1999-4923/6/3/447
:) Nice volume too. Some of it taking gains but also looks like some new buyers...
Long...
It's been exactly one month today since the expanded study started. Volume today and yesterday above the 30 & 100 dma.
I wonder how the mice being treated with Cell in a Box(R) technology are doing?
Maybe, pretty well? Time will tell but it sure appears interest in this technology is picking up.
:)
http://www.nasdaq.com/press-release/pharmacyte-biotech-initiates-expanded-followup-study-in-the-united-states-on-the-accumulation-of-20150219-00656
I did like the volume today. And I wonder how our mice are doing? Let's see what the rest of the week brings. I am hoping for more growing interest in Cell in a Box(R) technology.
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration's (FDA) Orphan Drug designation. Armed with the FDA's Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
Here's how it works: About 10,000 live cells capable of converting ifosfamide, an inactive chemotherapy drug when given intravenously, into its cancer killing form are encapsulated into unique and proprietary pin head-sized, porous capsules which form the company's live-cell encapsulation technology. A number of these capsules or "factory" of cells are strategically placed right at the site of the pancreatic tumor. They convert ifosfamide from an inactive drug to an active cancer-killing drug at the source of the cancer, not where it is normally converted -- in the liver.
The chemotherapy drug ifosfamide is carried by the patient's blood through the porous capsules where it is immediately converted into a cancer fighter -- again, right at the site of the tumor. This is targeted chemotherapy in every sense of the word with benefits not normally seen when a patient is undergoing chemotherapy.
Using Cell-in-Box allows PharmaCyte Biotech to use only one-third the normal dose of ifosfamide normally given to fight cancer. The proximity of the activation to the tumor site lessens the amount of ifosfamide required and, in turn, virtually eliminates the side effects usually seen with chemotherapy. The unique properties of the Cell-in-a-Box capsules cover the gamut of durability and provide the ability to be shipped anywhere in the world to be used when needed. The capsules and the cells within them have the ability to be frozen and stored for, at least, five years and can then be thawed for use to fight cancer in humans. These capsules are designed in such a way that completely protects the cells from any attack by the immune system. No other encapsulation technology in the world has these properties.
Pancreatic cancer is a notoriously stubborn disease that hides behind a fortified wall of tissue while becoming entangled with blood vessels and organs, often creating an inoperable condition with a bleak prognosis of life expectancy -- mostly measured in months, not years. In fact, pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. and has the highest mortality rate amongst major cancers with 74 percent of patients dying within the first 12 months of diagnosis.
Despite ongoing efforts, this rate of death hasn't changed substantially in nearly four decades. Gemcitabine, sold under the brand name Gemzar™ by Eli Lilly, has long been the industry standard, either as a single agent or as part of a cocktail of drugs. Most recently, Celgene received FDA approval as the gold standard treatment for advanced pancreatic cancer with its Abraxane plus gemcitabine combination. As the numbers show, though, there is still plenty of room to improve clinical outcomes, meaning that a new therapy has the potential to capture a large market share.
With that in mind, encouraging clinical data can be met with great acclaim and financial reward, such as Merrimack Pharmaceuticals striking a deal with healthcare giant Baxter International Inc. in September 2014 to develop and commercialize the experimental cancer drug called MM-398 for pancreatic cancer outside the U.S. and Taiwan. MM-398 is an investigational nanotherapeutic consisting of the chemotherapeutic irinotecan, encapsulated in a liposomal sphere that in a Phase 3 clinical trial in combination with 5-flourouracil and leucovorin in post-gemcitabine metastatic pancreatic patients achieved a median survival rate of 6.1 months versus 4.2 months for patients on 5-flourouracil and leucovorin alone.
In the agreement, Merrimack received $100 million upfront and is entitled to up to another $870 million in future payments based upon milestones being achieved.
Previously, in a Phase 1/2 study, Cell-in-a-Box plus ifosfamide almost doubled median survival time and the one-year survival rate in patients as compared to historical data for Gemzar. PharmaCyte Biotech is gearing up for a larger Phase 2b study in which their combination will be compared directly to Celgene FDA-approved Abraxane plus gemcitabine combination.
In December, the FDA granted an Orphan Drug designation for Cell-in-a-Box/ifosfamide for the treatment of pancreatic cancer, paving the way for potential developmental and commercialization benefits. Orphan Drug designations from the FDA are provided only to therapies for life threatening or rare diseases, defined by less than 200,000 diagnoses annually. Importantly, the designation validates the technology and brings with it special assistance from the FDA in the development of the drug and up to seven additional years of marketing exclusivity in the U.S. if it makes it to market, in addition to possible exemptions or reductions in regulatory fees and taxes.
PharmaCyte Bioech ($70 million market capitalization) will undoubtedly be looking to follow in the footsteps of its larger peer Merrimack ($1.2 billion market capitalization), who received and Orphan Drug designation for MM-398 for pancreatic cancer in 2011. In November 2014, a Fast Track designation, a status that carries with it different benefits for expediting development, was awarded to MM-398.
The commencement of PharmaCyte Biotech's Phase 2b clinical trial, expected this year, will be another step in the right direction for proving the potency and low toxicity of Cell-in-a-Box technology. And, taking direct aim at one of the most high profile pancreatic drug combinations today in Abraxane plus gemcitabine will likely increase the profile on PharmaCyte Biotech and the potential prowess of its novel therapy, so much so that it could become the treatment of choice for advanced pancreatic cancer.
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G035975-001.htm
"Using Cell-in-Box allows PharmaCyte Biotech to use only one-third the normal dose of ifosfamide normally given to fight cancer. The proximity of the activation to the tumor site lessens the amount of ifosfamide required and, in turn, virtually eliminates the side effects usually seen with chemotherapy. The unique properties of the Cell-in-a-Box capsules cover the gamut of durability and provide the ability to be shipped anywhere in the world to be used when needed. The capsules and the cells within them have the ability to be frozen and stored for, at least, five years and can then be thawed for use to fight cancer in humans. These capsules are designed in such a way that completely protects the cells from any attack by the immune system. No other encapsulation technology in the world has these properties."
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G035975-001.htm
Great post, bill. We have truly accomplished a lot over the past year. Thanks...
Pharmacyte Biotech Initiates Expanded Follow-up Study in the United States on the Accumulation of Malignant Ascites Fluid
SILVER SPRING, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a-Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid.
"We are looking forward to the results of this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady," commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
In the initial study, mice given an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups. There were 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.
The follow-up study will use the same ES-2 ovarian cancer model. In this study, the mice will be divided into 13 different treatment groups, with 10 mice in each group. The follow-up study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon. The study will be conducted by Translational Drug Development (TD2) in the U.S. which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2.
The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it is painful and can cause breathing and other serious problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. PharmaCyte Biotech expects that its pancreatic cancer treatment will ultimately prove to be effective in slowing the accumulation of malignant ascites fluid and thus reduce the number of withdrawals of the fluid that patients must endure over a given period of time.
Read more: http://www.nasdaq.com/press-release/pharmacyte-biotech-initiates-expanded-followup-study-in-the-united-states-on-the-accumulation-of-20150219-00656#ixzz3Ug8dX1YY
From the recent 10Q, PMCB...
"The Company is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of abdominal cancers using the Cell-in-a-Box ® technology."
"The strategy of the Company to achieve its goals includes...:
The conducting of preclinical studies and clinical trials that will examine the effectiveness of the Company’s pancreatic cancer treatment in ameliorating the pain and accumulation of malignant ascites fluid in the abdomen that are characteristic of pancreatic cancer. These studies and trials will be conducted by Translational Drug Development in the United States"
http://www.td2inc.com/about
http://www.td2inc.com/about/leadership
http://secfilings.com/searchresultswide.aspx?link=1&filingid=10563865
Here is a video clip of Dr Von Hoff. Truly an amazing man.. We are blessed that he was intersted in Cell in a Box(R) technology. And we are hopeful the blessing will be passed on to others in need.
It would be nice to get an honorable mention on March 27. But as you said, whenever he mentions Cell in a Box(R) technology, we will see a boost.
It's like driving to Disneyland... "Are we there yet?" :)
It will be amazing when we arrive!
The value of CiaB technology reflecting in the pps is imminent. Studies and trials take time. Only one of these need to report good results and value will be noted. Then, when this gets to market, the value will be exponential...
Progress in the Cancer Program
PharmaCyte Biotech's treatment (Cell-in-a-Box® plus low-doses of ifosfamide) for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in late December of 2014.
On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box® plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S. is the third quarter of 2015.
Preparations for the Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer are ongoing. Major documents, including the Investigators Brochure and a clinical protocol (a recipe for conducting the clinical trial) are in preparation, with the assistance of Clinical Network Services (CNS) - one of Australia's leading Clinical Research Organizations. The target date for the initiation of the Phase 2b clinical trial in Australia is the third quarter of 2015.
We initially reported that we expected to begin our Phase 2b clinical trial in the first quarter of 2015; however, we are awaiting the Good Manufacturing Practices (GMP) regulatory approval process that our partner, Austrianova, is currently involved with in order to get the GMP-compliant facility at the Thai Science Park in Bangkok, Thailand, approved to produce Cell-in-a-Box® capsules for human clinical trials. Austrianova believes the process will now be completed in the third quarter of 2015.
Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers - such as brain and pancreatic cancer.
Progress in the Diabetes Program
Studies are in progress at the University of Veterinary Medicine, Vienna (UVM) to determine if Melligen (human, non-pancreatic, insulin-producing) cells are tumorigenic and to establish parameters by which these cells (human, non-pancreatic, insulin-producing) can produce and store insulin in response to glucose levels in their surroundings. The coordinator for these studies is Dr. Constantine Konstantoulas of UVM.
An exclusive license to use the Melligen cells developed by Prof. Ann Simpson of the University of Technology Sydney (UTS) in Australia has been obtained from UTS by PharmaCyte Biotech from UTS.
Dr. Eva-Maria Brandtner has been appointed Director of the Diabetes Research Program. Dr. Brandtner, presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria, was responsible for studies with the Melligen cells during her previous tenure with our partner, Austrianova, at its Chief Scientist.
- See more at: http://globenewswire.com/news-release/2015/03/16/715481/10124852/en/PharmaCyte-Biotech-Provides-Update-on-Corporate-Developments-and-Progress-With-Cancer-and-Diabetes-Programs.html#sthash.IFzp8H66.dpuf
There are a lot of things at PharmaCyte that make shareholders happy, the current pps is not one of them. However, we do know this is contrived and does not represent the real value of Cell in a Box technology.
Our CEO and the others on the board are doing everything in their control to create shareholder value - which is imminent. We can wait on being happy about the pps.
"As to the update, we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future. Our priority is and always has been to maximize shareholder value, and we are working diligently to reach that objective," added Mr. Waggoner.
http://globenewswire.com/news-release/2015/03/16/715481/10124852/en/PharmaCyte-Biotech-Provides-Update-on-Corporate-Developments-and-Progress-With-Cancer-and-Diabetes-Programs.html
That is what happens when I do it too. That is why I do this. :). LOL
Note that you do have 15 minutes to edit your message. Look on the right of your screen. I love and use this feature quite often...
Shareholder update...
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, stated, "Given all of the developments that have occurred since our last update, we believe it is an appropriate time to update our shareholders on developments and to highlight and briefly summarize what is in store for PharmaCyte Biotech in the coming days. Before doing so, however, we would like to address two issues that reportedly are of significant concern to a number of our shareholders. The first has to do with whether a reverse stock split is imminent. The second is whether we have access to capital to move forward with our clinical trials. PharmaCyte Biotech has no current plans to effectuate a reverse stock split. In addition, our cash position remains strong and our ability to raise capital continues to be very favorable."
"As to the update, we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future. Our priority is and always has been to maximize shareholder value, and we are working diligently to reach that objective," added Mr. Waggoner.
Progress in the Cancer Program
PharmaCyte Biotech's treatment (Cell-in-a-Box® plus low-doses of ifosfamide) for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in late December of 2014.
On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box® plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S. is the third quarter of 2015.
Preparations for the Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer are ongoing. Major documents, including the Investigators Brochure and a clinical protocol (a recipe for conducting the clinical trial) are in preparation, with the assistance of Clinical Network Services (CNS) - one of Australia's leading Clinical Research Organizations. The target date for the initiation of the Phase 2b clinical trial in Australia is the third quarter of 2015.
We initially reported that we expected to begin our Phase 2b clinical trial in the first quarter of 2015; however, we are awaiting the Good Manufacturing Practices (GMP) regulatory approval process that our partner, Austrianova, is currently involved with in order to get the GMP-compliant facility at the Thai Science Park in Bangkok, Thailand, approved to produce Cell-in-a-Box® capsules for human clinical trials. Austrianova believes the process will now be completed in the third quarter of 2015.
Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers - such as brain and pancreatic cancer.
Progress in the Diabetes Program
Studies are in progress at the University of Veterinary Medicine, Vienna (UVM) to determine if Melligen (human, non-pancreatic, insulin-producing) cells are tumorigenic and to establish parameters by which these cells (human, non-pancreatic, insulin-producing) can produce and store insulin in response to glucose levels in their surroundings. The coordinator for these studies is Dr. Constantine Konstantoulas of UVM.
An exclusive license to use the Melligen cells developed by Prof. Ann Simpson of the University of Technology Sydney (UTS) in Australia has been obtained from UTS by PharmaCyte Biotech from UTS.
Dr. Eva-Maria Brandtner has been appointed Director of the Diabetes Research Program. Dr. Brandtner, presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria, was responsible for studies with the Melligen cells during her previous tenure with our partner, Austrianova, at its Chief Scientist.
Developments at the Corporate Level
The Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to emphasize that it has fully transitioned from a nutraceutical company to a purely biotechnology company.
Changes have been and are being made at the Board of Directors level, with additional member candidates to the Board in their final interview process; these new members will be widely experienced in the life sciences.
Waggoner concluded, "We are pleased to offer this update to our shareholders. We trust that they will agree that significant progress is being made on all fronts."
Yep, it's a win win for all on board...
Isn't it interesting how the PPS drops with good news. Nothing but a tactic, imo, to make it appear that the market is rejecting the updates. In my humble opinion, I think it is the Market Makers themselves who are not happy with the news. After all, they are the ones responsible for making the market and your average investor does not sell on good news. Not unless they are worried as a result of a contrived drop in pps.
"Stand for something, or fall for anything."
Well we just recently made our first payment for licensing rights to use cannabanoids with Cell in a Box technology and we are currently working on a new cell line to be used.
"Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers - such as brain and pancreatic cancer."
Amazing how many uses for Cell in a Box that we are working on...
"Changes have been and are being made at the Board of Directors level, with additional member candidates to the Board in their final interview process; these new members will be widely experienced in the life sciences."
Nice... Good news today on many fronts...
"We are pleased to offer this update to our shareholders. We trust that they will agree that significant progress is being made on all fronts."
This should make all stakeholders very happy...
"On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box® plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S is the third quarter 2015.
I told you I like this CEO. We have had longs and others mention concerns about a RS and having the ability to pay for trials. It was very considerate of him to make a specific statement addressing these concerns.
Now, we continue to practice patience and wait for study results and upcoming trials.
The more attacks the more confident I am we are doing well and on the right track. No one tries to take down a loser. But they sure will try to shoot down a rising star.
$PMCB
Long...
Sorry about your loss...
I think Dr Von Hoff may be able to help us raise money for Phase 1. I don't see him letting money get in the way of a novel "quality of life" treatment for all abdominal cancers. These trials should not take as long as 2b either, imo. So, I think Dr Von Hoff's trials are key for short term gains which should help fund future trials for pancreatic cancer and diabetes.
:)
Long...
This particular SEC Iink takes you to all the flings an entity has with the Securities and Exchange Commission.
"All companies, foreign and domestic, are required to file registration statements, periodic reports, and other forms electronically through EDGAR. Anyone can access and download this information for free. Here you'll find links to a complete list of filings available through EDGAR and instructions for searching the EDGAR database."
http://www.sec.gov/cgi-bin/browse-edgar?company=Nuvilex+&owner=exclude&action=getcompany
One of these filings is a Confidential Treatment Order which requires a more in depth review by the SEC. This company is well reviewed by government agencies. The most recent CTO filing was just this past January.
https://www.law.cornell.edu/cfr/text/17/200.83
Hey, Jimmy Joe. Dr Von Hoff's study was designed by him for malignant ascites and pain associated with all abdominal cancers, a "quality if life" treatment plan. The first study started August 2014 and the extended study with 12 treatments and a control group started this past February.
This second extended study for malignant ascites will be followed by a Phase 1 so they can also test for pain which can only be validated in humans. The plan is this trial will start in 3Q.
2b is for pancreatic cancer and will start sometime this year.
Hope this helps...